PMID- 23125179
OWN - NLM
STAT- MEDLINE
DCOM- 20130613
LR  - 20181202
IS  - 1932-8494 (Electronic)
IS  - 1932-8486 (Linking)
VI  - 296
IP  - 1
DP  - 2013 Jan
TI  - TFPI-2 downregulates multidrug resistance protein in 5-FU-resistant human 
      hepatocellular carcinoma BEL-7402/5-FU cells.
PG  - 56-63
LID - 10.1002/ar.22611 [doi]
AB  - Tissue factor pathway inhibitor-2 (TFPI-2) is known to induce apoptosis and to 
      suppress tumor metastasis in several types of cancer cells. However, there is 
      little known about its reversal effect on chemoresistant tumor cells. This study 
      investigated the effect of TFPI-2 in 5-fluorouracil (5-FU)-resistant human 
      hepatocellular cancer BEL-7402/5-FU cells in vitro. We constructed TFPI-2 
      overexpression BEL-7402/5-FU cell lines and explored resistance index (RI) of 
      5-FU, function of the P-glycoprotein (P-gp) efflux pump, and the mRNA and protein 
      expression of drug resistance gene, including multidrug resistance gene (MDR1), 
      lung-resistance protein (LRP), multidrug resistance-associated protein (MRP1), 
      glutathione-S-transferase-pi (GST-pi), excision repair cross-complementing gene 1 
      (ERCC1), and p38 phosphorylation. We found that TFPI-2 improved the RI of 5-FU 
      and inhibited P-gp function. Western blotting and real-time PCR revealed that 
      TFPI-2 also decreased mRNA and protein expression of MDR1, LRP, MRP1, GST-pi, and 
      ERCC1, whereas p38 phosphorylation was increased. We considered that TFPI-2 
      reduces 5-FU resistance in BEL-7402/5-FU cells, and the mechanism appears to 
      involve p38-mediated downregulation of drug resistance gene expression such as 
      MDR1, LRP, MRP1, GST-pi, and ERCC1.
CI  - Copyright (c) 2012 Wiley Periodicals, Inc.
FAU - Lu, Fei
AU  - Lu F
AD  - Microsurgical Ward Section, The First Affiliated Hospital of Henan University of 
      Science and Technology, Luoyang, China.
FAU - Hou, Yong-Qiang
AU  - Hou YQ
FAU - Song, Ying
AU  - Song Y
FAU - Yuan, Zheng-Jiang
AU  - Yuan ZJ
LA  - eng
PT  - Journal Article
DEP - 20121104
PL  - United States
TA  - Anat Rec (Hoboken)
JT  - Anatomical record (Hoboken, N.J. : 2007)
JID - 101292775
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 1)
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Glycoproteins)
RN  - 0 (Multidrug Resistance-Associated Proteins)
RN  - 0 (Serine Proteinase Inhibitors)
RN  - 0 (Vault Ribonucleoprotein Particles)
RN  - 0 (major vault protein)
RN  - 0 (tissue-factor-pathway inhibitor 2)
RN  - EC 3.1.- (ERCC1 protein, human)
RN  - EC 3.1.- (Endonucleases)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics/*metabolism
MH  - Antimetabolites, Antineoplastic/pharmacology/therapeutic use
MH  - Apoptosis/drug effects
MH  - Carcinoma, Hepatocellular/*drug therapy/metabolism/pathology
MH  - Cell Line, Tumor
MH  - DNA-Binding Proteins/genetics/metabolism
MH  - Down-Regulation/*drug effects
MH  - *Drug Resistance, Neoplasm
MH  - Endonucleases/genetics/metabolism
MH  - Fluorouracil/pharmacology/*therapeutic use
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Glycoproteins/*pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Liver Neoplasms/*drug therapy/metabolism/pathology
MH  - Multidrug Resistance-Associated Proteins/genetics/metabolism
MH  - Serine Proteinase Inhibitors/pharmacology
MH  - Vault Ribonucleoprotein Particles/genetics/metabolism
EDAT- 2012/11/06 06:00
MHDA- 2013/06/14 06:00
CRDT- 2012/11/06 06:00
PHST- 2012/05/21 00:00 [received]
PHST- 2012/08/22 00:00 [accepted]
PHST- 2012/11/06 06:00 [entrez]
PHST- 2012/11/06 06:00 [pubmed]
PHST- 2013/06/14 06:00 [medline]
AID - 10.1002/ar.22611 [doi]
PST - ppublish
SO  - Anat Rec (Hoboken). 2013 Jan;296(1):56-63. doi: 10.1002/ar.22611. Epub 2012 Nov 
      4.